Cargando…
High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244674/ https://www.ncbi.nlm.nih.gov/pubmed/34089598 http://dx.doi.org/10.1093/cid/ciab515 |
_version_ | 1783715977503965184 |
---|---|
author | Nkuba, Antoine N Makiala, Sheila M Guichet, Emilande Tshiminyi, Paul M Bazitama, Yannick M Yambayamba, Marc K Kazenza, Benito M Kabeya, Trésor M Matungulu, Elysee B Baketana, Lionel K Mitongo, Naomi M Thaurignac, Guillaume Leendertz, Fabian H Vanlerberghe, Veerle Pelloquin, Raphaël Etard, Jean-François Maman, David Mbala, Placide K Ayouba, Ahidjo Peeters, Martine Muyembe, Jean-Jacques T Delaporte, Eric Ahuka, Steve M |
author_facet | Nkuba, Antoine N Makiala, Sheila M Guichet, Emilande Tshiminyi, Paul M Bazitama, Yannick M Yambayamba, Marc K Kazenza, Benito M Kabeya, Trésor M Matungulu, Elysee B Baketana, Lionel K Mitongo, Naomi M Thaurignac, Guillaume Leendertz, Fabian H Vanlerberghe, Veerle Pelloquin, Raphaël Etard, Jean-François Maman, David Mbala, Placide K Ayouba, Ahidjo Peeters, Martine Muyembe, Jean-Jacques T Delaporte, Eric Ahuka, Steve M |
author_sort | Nkuba, Antoine N |
collection | PubMed |
description | BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies in the general population in Kinshasa. METHODS: We conducted a cross-sectional, household-based serosurvey between 22 October 2020 and 8 November 2020. Participants were interviewed at home and tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins in a Luminex-based assay. A positive serology was defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections. RESULTS: A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 [61.2%] women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI: 14.0–19.5%). The estimated infection-to-case ratio was 292:1. Prevalence was higher among participants ≥40 years than among those <18 years (21.2% vs 14.9%, respectively; P < .05). It was also higher in participants who reported hospitalization than among those who did not (29.8% vs 16.0%, respectively; P < .05). However, differences were not significant in the multivariate model (P = .1). CONCLUSIONS: The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases reported. These results justify the organization of a sequential series of serosurveys by public health authorities to adapt response measures to the dynamics of the pandemic. |
format | Online Article Text |
id | pubmed-8244674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82446742021-07-01 High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey Nkuba, Antoine N Makiala, Sheila M Guichet, Emilande Tshiminyi, Paul M Bazitama, Yannick M Yambayamba, Marc K Kazenza, Benito M Kabeya, Trésor M Matungulu, Elysee B Baketana, Lionel K Mitongo, Naomi M Thaurignac, Guillaume Leendertz, Fabian H Vanlerberghe, Veerle Pelloquin, Raphaël Etard, Jean-François Maman, David Mbala, Placide K Ayouba, Ahidjo Peeters, Martine Muyembe, Jean-Jacques T Delaporte, Eric Ahuka, Steve M Clin Infect Dis Major Articles and Commentaries BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies in the general population in Kinshasa. METHODS: We conducted a cross-sectional, household-based serosurvey between 22 October 2020 and 8 November 2020. Participants were interviewed at home and tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins in a Luminex-based assay. A positive serology was defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections. RESULTS: A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 [61.2%] women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI: 14.0–19.5%). The estimated infection-to-case ratio was 292:1. Prevalence was higher among participants ≥40 years than among those <18 years (21.2% vs 14.9%, respectively; P < .05). It was also higher in participants who reported hospitalization than among those who did not (29.8% vs 16.0%, respectively; P < .05). However, differences were not significant in the multivariate model (P = .1). CONCLUSIONS: The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases reported. These results justify the organization of a sequential series of serosurveys by public health authorities to adapt response measures to the dynamics of the pandemic. Oxford University Press 2021-06-05 /pmc/articles/PMC8244674/ /pubmed/34089598 http://dx.doi.org/10.1093/cid/ciab515 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles and Commentaries Nkuba, Antoine N Makiala, Sheila M Guichet, Emilande Tshiminyi, Paul M Bazitama, Yannick M Yambayamba, Marc K Kazenza, Benito M Kabeya, Trésor M Matungulu, Elysee B Baketana, Lionel K Mitongo, Naomi M Thaurignac, Guillaume Leendertz, Fabian H Vanlerberghe, Veerle Pelloquin, Raphaël Etard, Jean-François Maman, David Mbala, Placide K Ayouba, Ahidjo Peeters, Martine Muyembe, Jean-Jacques T Delaporte, Eric Ahuka, Steve M High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title | High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title_full | High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title_fullStr | High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title_full_unstemmed | High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title_short | High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey |
title_sort | high prevalence of anti–severe acute respiratory syndrome coronavirus 2 (anti–sars-cov-2) antibodies after the first wave of coronavirus disease 2019 (covid-19) in kinshasa, democratic republic of the congo: results of a cross-sectional household-based survey |
topic | Major Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244674/ https://www.ncbi.nlm.nih.gov/pubmed/34089598 http://dx.doi.org/10.1093/cid/ciab515 |
work_keys_str_mv | AT nkubaantoinen highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT makialasheilam highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT guichetemilande highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT tshiminyipaulm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT bazitamayannickm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT yambayambamarck highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT kazenzabenitom highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT kabeyatresorm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT matunguluelyseeb highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT baketanalionelk highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT mitongonaomim highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT thaurignacguillaume highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT leendertzfabianh highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT vanlerbergheveerle highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT pelloquinraphael highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT etardjeanfrancois highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT mamandavid highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT mbalaplacidek highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT ayoubaahidjo highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT peetersmartine highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT muyembejeanjacquest highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT delaporteeric highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey AT ahukastevem highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey |